Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)
Status:
Withdrawn
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective
for the treatment of children and adolescents (ages 10-17) with Bipolar l Disorder (Manic or
Mixed).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.